Bayer, Boehringer extend access to clinical trial data

Bayer and Boehringer Ingelheim outlined plans to increase access to their clinical trial data. Both are using to share clinical study reports and de-identified patient level-data with reseachers upon request. GlaxoSmithKline ($GSK), Novartis ($NVS), Roche ($RHHBY) and Sanofi ($SNY) also use the portal to manage data requests. Bayer release | Boehringer release

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.